As HER2, PD-L1, and MSI are established biomarkers, and EBV and FGFR2b are emerging biomarkers for biomarker-based therapies in patients with GC,27 we compared CLDN18.2 expression status with HER2, PD-L1, MSI, EBV, and FGFR2b. This evidence concerns the gene ERBB2 and gastric cancer.